Rational development of multicomponent mRNA vaccine candidates against mpox

References

• Lum FM, Torres-Ruesta A, Tay MZ, et al. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol. 2022 Oct;22(10):597–613.
   PubMed Web of Science ®Google Scholar
• eBioMedicine. Monkeypox virus outbreak: can evolution guide us to new treatments or vaccines? EBioMedicine. 2022 Aug;82:104221.
   PubMed Web of Science ®Google Scholar
• https://worldhealthorg.shinyapps.io/mpx_global/.
   Google Scholar
• Tarin-Vicente EJ, Alemany A, Agud-Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661–669.
   PubMed Web of Science ®Google Scholar
• Fogg C, Lustig S, Whitbeck JC, et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol. 2004 Oct;78(19):10230–7.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Thompson E, Wilhelmsen C, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol. 2004 May;78(9):4433–4443.
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Earl PL, Eller LA, et al. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590–4595.
   PubMed Web of Science ®Google Scholar
• Hatch GJ, Graham VA, Bewley KR, et al. Assessment of the protective effect of imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol. 2013 Jul;87(14):7805–7815.
   PubMed Web of Science ®Google Scholar
• Garza NL, Hatkin JM, Livingston V, et al. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine. 2009 Sep 4;27(40):5496–5504.
   PubMed Web of Science ®Google Scholar
• Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 2004 Jan;4(1):15–25.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox.
   Google Scholar
• https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-monkeypox-disease.
   Google Scholar
• Zaeck LM, Lamers MM, Verstrepen BE, et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2023 Jan;29(1):270–278.
   PubMed Web of Science ®Google Scholar
• Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. JAMA. 2021 Apr 6;325(13):1318–1320.
   PubMed Web of Science ®Google Scholar
• Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–1283.e16.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Zhang Y, Tarke A, et al. Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. Cell Host Microbe. 2022 Dec 14;30(12):1662–1670.e4.
   PubMed Web of Science ®Google Scholar
• Gilchuk I, Gilchuk P, Sapparapu G, et al. Cross-Neutralizing and protective human antibody specificities to poxvirus infections. Cell. 2016 Oct 20;167(3):684–694.e9.
   PubMed Web of Science ®Google Scholar
• Esposito JJ, Obijeski JF, Nakano JH. The virion and soluble antigen proteins of variola, monkeypox, and vaccinia viruses. J Med Virol. 1977;1(2):95–110.
   PubMed Web of Science ®Google Scholar
• Rothenburg S, Yang Z, Beard P, et al. Monkeypox emergency: urgent questions and perspectives. Cell. 2022 Sep 1;185(18):3279–3281.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 2003 Feb 1;306(1):181–195.
   PubMed Web of Science ®Google Scholar
• Sakhatskyy P, Wang S, Chou TH, et al. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology. 2006 Nov 25;355(2):164–174.
   PubMed Web of Science ®Google Scholar
• Mucker EM, Golden JW, Hammerbeck CD, et al. A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge. J Virol. 2022 Feb 9;96(3):e0150421.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Golden JW, Ferro AM, et al. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine. 2007 Feb 26;25(10):1814–1823.
   PubMed Web of Science ®Google Scholar
• Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine. 2008 Jun 25;26(27–28):3507–3515.
   PubMed Web of Science ®Google Scholar
• Law M, Smith GL. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology. 2001 Feb 1;223(1):132–142.
   Google Scholar
• Hooper JW, Custer DM, Schmaljohn CS, et al. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 2000 Jan 20;266(2):329–339.
   PubMed Web of Science ®Google Scholar
• Galmiche MC, Goenaga J, Wittek R, et al. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology. 1999 Feb 1;254(1):71–80.
   PubMed Web of Science ®Google Scholar
• Hirao LA, Draghia-Akli R, Prigge JT, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis. 2011 Jan 1;203(1):95–102.
   PubMed Web of Science ®Google Scholar
• Fang M, Sigal LJ. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol. 2005 Nov 15;175(10):6829–6836.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Aldaz-Carroll L, Ortiz AM, et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine. 2007 Jan 26;25(7):1214–1224.
   PubMed Web of Science ®Google Scholar
• Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005 Jul;11(7):740–747.
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Langland JO, Kibler KV, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009 Oct;84(1):1–13.
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Hensley LE, Martinez MJ, et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15196–15200.
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Dasgupta A, Pinilla C, et al. Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14567–14572.
   PubMed Web of Science ®Google Scholar
• Byrd D, Shepherd N, Lan J, et al. Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination. J Virol. 2014 Jun;88(12):6819–6831.
   PubMed Web of Science ®Google Scholar
• Hickman HD, Reynoso GV, Ngudiankama BF, et al. Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe. 2013 Feb 13;13(2):155–168.
   PubMed Web of Science ®Google Scholar
• Remakus S, Rubio D, Lev A, et al. Memory CD8(+) T cells can outsource IFN-gamma production but not cytolytic killing for antiviral protection. Cell Host Microbe. 2013 May 15;13(5):546–557.
   PubMed Web of Science ®Google Scholar
• Goulding J, Abboud G, Tahiliani V, et al. CD8 t cells use IFN-gamma to protect against the lethal effects of a respiratory poxvirus infection. J Immunol. 2014 Jun 1;192(11):5415–5425.
   PubMed Web of Science ®Google Scholar
• Isidro J, Borges V, Pinto M, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022 Aug;28(8):1569–1572.
   PubMed Web of Science ®Google Scholar
• Sun M-X, Huang X-Y, Qin C-F. Novel clinical and genomic signatures of the 2022 monkeypox virus. Zoonoses. 2023;3(1).
   Google Scholar
• Perumal Arumugam Desingu KN. Genomic regions insertion and deletion in Monkeypox virus causing multi-country outbreak-2022. bioRxiv. 2022.
   Google Scholar
• Hooper JW, Ferro AM, Golden JW, et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine. 2009 Dec 11;28(2):494–511.
   PubMed Web of Science ®Google Scholar
• Franceschi V, Parker S, Jacca S, et al. BoHV-4-Based vector single heterologous antigen delivery protects STAT1(-/-) mice from Monkeypoxvirus Lethal challenge. PLoS Negl Trop Dis. 2015 Jun;9(6):e0003850.
   PubMed Web of Science ®Google Scholar
• Hutson CL, Gallardo-Romero N, Carroll DS, et al. Analgesia during Monkeypox Virus experimental challenge studies in Prairie dogs (Cynomys ludovicianus). J Am Assoc Lab Anim Sci. 2019 Jul 1;58(4):485–500.
   PubMed Web of Science ®Google Scholar
• Russo AT, Berhanu A, Bigger CB, et al. Co-administration of tecovirimat and ACAM2000 in non-human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2020 Jan 16;38(3):644-654.
   PubMed Web of Science ®Google Scholar